Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/14811
Title: Assessing the need for quality-adjusted cost–effectiveness studies of nanotechnological cancer therapies
Authors: Bosetti, Rita 
Marneffe, Wim 
Vereeck, Lode 
Issue Date: 2013
Source: Nanomedicine, 8 (3), p. 487-497
Abstract: New therapies, such as nanotechnology-based cancer treatments, typically entail high acquisition costs. Their use can be justified, however, by their superior cost-effectiveness. This article assesses the quality of cost- effectiveness analyses of nanotechnical cancer therapies by screening nine major studies. They conclude that nanotherapies are cost effective for the treatment of ovarian and breast cancer, as well as multiple myeloma, but not for other types of cancer. However, these studies have some serious methodological flaws. Typically, the results are not quality adjusted, although both length and quality of life are affected. Moreover, only fragmented direct medical costs are included, neglecting indirect costs that impose a significant economic burden on patients and society. Finally, cost definitions differ widely making any comparison between studies virtually impossible. This article concludes that economic research of nanotechnology-based therapeutics is still in its infancy. It warns that incomplete economic analysis may lead to inefficient policy recommendations.
Document URI: http://hdl.handle.net/1942/14811
ISSN: 1743-5889
e-ISSN: 1748-6963
DOI: 10.2217/nnm.13.15
ISI #: 000315973900021
Category: A1
Type: Journal Contribution
Validations: ecoom 2014
Appears in Collections:Research publications

Show full item record

SCOPUSTM   
Citations

10
checked on Sep 2, 2020

WEB OF SCIENCETM
Citations

11
checked on May 13, 2022

Page view(s)

48
checked on May 15, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.